Pregnancy Diagnostics Target Metabolomic Diagnostics for healthcare providers and laboratories focused on pregnancy care to advance early risk screening for preeclampsia, gestational diabetes, preterm birth, and IUGR with biomarker panels translated into clinical assays.

Clinical Partnerships Leverage existing and upcoming collaborations with foundations and biotech partners (eg Preeclampsia Foundation, Renegade/bio networks) to co-develop and validate diagnostic solutions, accelerating field adoption and credibility.

Early Stage Funding Capitalize on recent and past funding rounds to expand product development, regulatory readiness (ISO 9001 alignment), and clinical validation studies, offering fundable milestones to investors and strategic sponsors.

Strategic Markets Position diagnostics for prenatal care markets with payer discussions and hospital labs, emphasizing cost savings from complication prevention and personalized care pathways to drive adoption and reimbursement alignment.

Global Outreach Expand visibility through award recognition and international partnerships to attract global lab networks and distributors, enabling scalable deployment of biomarker-based assays in diverse healthcare systems.